Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMYD2 | Q9NRG4 | 3/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | IDO1 | P14902 | 4/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.36 |
| ▸ | AXL | P30530 | 1/20 | 0.32 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.32 |
| ▸ | MERTK | Q12866 | 1/20 | 0.32 |
| ▸ | TEAD1 | P28347 | 1/20 | 0.30 |
| ▸ | TEAD3 | Q99594 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30955729 | 1.00 | SMYD2 (0.43) | SMYD2CYP3A4HTTSMN1; SMN2IDO1 | |
| SCHEMBL30955759 | 1.00 | SMYD2 (0.43) | SMYD2CYP3A4HTTSMN1; SMN2IDO1 | |
| SCHEMBL31644559 | 0.93 | SMYD2 (0.41) | SMYD2CYP3A4HTTSMN1; SMN2IDO1 | |
| SCHEMBL599855 | 0.89 | SMYD2 (0.43) | SMYD2CYP3A4HTTSMN1; SMN2IDO1 | |
| SCHEMBL2017541 | 0.89 | SMYD2 (0.43) | SMYD2CYP3A4HTTSMN1; SMN2IDO1 | |
| SCHEMBL15822129 | 0.87 | SMYD2 (0.37) | SMYD2CYP3A4HTTSMN1; SMN2CHRM2 | |
| SCHEMBL27156635 | 0.87 | SMYD2 (0.37) | SMYD2CYP3A4HTTSMN1; SMN2CHRM2 | |
| SCHEMBL15822127 | 0.87 | SMYD2 (0.37) | SMYD2CYP3A4HTTSMN1; SMN2CHRM2 | |
| SCHEMBL31644626 | 0.85 | SMYD2 (0.40) | SMYD2CYP3A4HTTSMN1; SMN2IDO1 | |
| SCHEMBL31645002 | 0.85 | SMYD2 (0.40) | SMYD2CYP3A4HTTSMN1; SMN2IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4558495-A1 | HETEROARYL COMPOUNDS AS LIGAND DIRECTED DEGRADERS OF IRAK4 | Bristol-Myers Squibb Company (US) | 2025-05-28 | — | — | EP | disclosed |
| US-20240109881-A1 | Heteroaryl Compounds as Ligand Directed Degraders of IRAK4 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-04-04 | — | — | US | disclosed |
| WO-2024020084-A1 | HETEROARYL COMPOUNDS AS LIGAND DIRECTED DEGRADERS OF IRAK4 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240109881-A1 | Heteroaryl Compounds as Ligand Directed Degraders of IRAK4 | IRAK4, IRAK2, IRAK3 | SMYD2 1851/4885CYP3A4 1957/4885HTT 1426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.